Skye Bioscience, Inc. (SKYE) Stock Price & Analysis
Skye Bioscience, Inc. (SKYE) rose 4.49% to USD 1.86 as of September 8, 2026 at 11:00 UTC, according to Nexqual real-time market data.
SKYE last closed at USD 1.78; the session ranged USD 1.77–1.95 on volume of 183,113 shares. Market capitalization is $8.24M, with a 52-week range of USD 1.64–39.92 (NCM). Source: Nexqual, September 8, 2026 at 11:00 UTC.
Key Statistics (as of September 8, 2026 at 11:00 UTC)
| Price | USD 1.86 |
|---|---|
| Change | ▲ 4.49% (up) |
| Previous Close | USD 1.78 |
| Open | USD 1.77 |
| Day Range | USD 1.77 – 1.95 |
| 52-Week Range | USD 1.64 – 39.92 |
| Volume | 183,113 shares |
| Market Cap | $8.24M |
| Exchange | NCM |
Technical Analysis (SKYE)
Nexqual's technical model rates SKYE "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 11:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.05 (oversold) |
| vs SMA50 | Below (USD 4.12) |
| MACD | -0.74 (negative) |
Analyst Ratings (SKYE)
Wall Street analysts rate SKYE "Buy" based on 4 analysts, with a mean price target of USD 68 (range USD 16–160), per Nexqual as of September 8, 2026 at 11:00 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 68 |
| High Target | USD 160 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (SKYE)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -1.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.55 vs est -2.11 ▲ beat |
| 2026-03-31 | USD -2.56 vs est -2.59 ▲ beat |
| 2025-12-31 | USD -2.95 vs est -2.45 ▼ miss |
| 2025-09-30 | USD -2.59 vs est -2.56 ▼ miss |
Source: Nexqual, September 8, 2026 at 11:00 UTC.
Financials & Fundamentals (SKYE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -233.87% |
| Current Ratio | 0.95 |
| Total Cash | $10.06M |
| Total Debt | $178,746 |
| Free Cash Flow | $-18.71M |
Source: Nexqual, September 8, 2026 at 11:00 UTC.
Financial Health Score (SKYE)
Nexqual rates Skye Bioscience, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 11:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$39M |
| Efficiency | Critical — ROE -234%, ROA -95.1% |
Ownership (SKYE)
| Insider Ownership | +4.24% |
|---|---|
| Institutional Ownership | +44.49% |
| Shares Outstanding | 4.43M |
| Float | 2.77M |
| Short % of Float | +4.75% |
Source: Nexqual, September 8, 2026 at 11:00 UTC.
Leadership (SKYE)
Skye Bioscience, Inc. is led by Punit S. Dhillon B.A. (age 45), President, CEO & Director, per Nexqual as of September 8, 2026 at 11:00 UTC.
| President, CEO & Director | Punit S. Dhillon B.A. (age 45) |
|---|---|
| CFO and Principal Financial & Accounting Officer | John P. Sharp (age 60) |
Major Backers & Investors (SKYE)
Notable institutional backers of Skye Bioscience, Inc. include 5AM Venture Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors, LP, according to Nexqual as of September 8, 2026 at 11:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| 5AM Venture Management, LLC | 27.33% |
| Versant Venture Management, LLC | 5.67% |
| Baker Bros. Advisors, LP | 4.45% |
| Sphera Funds Management Ltd. | 1.92% |
| Platinum Investment Management Ltd | 0.66% |
| Millennium Management | 0.56% |
| Fidelity | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.61% |
| BlackRock | 0.66% |
| Geode Capital | 0.62% |
Source: Nexqual, September 8, 2026 at 11:00 UTC.
From Skye Bioscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition to injectable therapies for overweight and obesity, Wegovy became the first FDA approved oral GLP-1 receptor agonist in December 2025 and other oral therapies are in development for treating overweight and obesity, including those being development by Eli Lilly, Structure Therapeutics, and Viking Therapeutics.
- Halozyme will also be the Company's exclusive supplier of clinical and commercial supplies of the active pharmaceutical ingredient ("API") for Halozyme's rHuPH20 bulk drug product.
- Review and approval of drugs and biologics in the United States In the United States, the Food and Drug Administration ("FDA") regulates drugs under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and its implementing regulations, and regulates biologics under the FDCA, the Public Health Service Act (the "PHSA"), and their implementing regulations.
- Intellectual Property The success of our product candidates will depend in large part on our ability to obtain and maintain patent and other legal protection for the proprietary technology, inventions and improvements we consider important to our business, prosecute our patent applications and defend any issued patents we obtain, preserve the confidentiality of our trade secrets, and operate without infringing the patents and proprietary rights of third parties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACCL | Acco Group Holdings Limited | USD 2.74 | ▲ 0% |
| SLSN | Solesence, Inc. | USD 0.85 | ▼ 6.7% |
| NVEC | NVE Corporation | USD 100.4 | ▲ 1.93% |
| NGEN | NervGen Pharma Corp. | USD 2.33 | ▲ 0% |
| VECO | Veeco Instruments Inc. | USD 44.67 | ▲ 3.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 11:00 UTC. This page is informational and not investment advice.